Is Mylan Off Base About Perrigo Prospects?
This article was originally published in The Tan Sheet
The company is confident it can take over it’s the OTC private label giant, but analysts, Perrigo management and investors seems to lack the same conviction. FTC and state court rulings remove additional roadblocks.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.